Corcept's Relacorilant Faces FDA Decision, Stock Volatility
Update: 2025-12-23
Description
Corcept Therapeutics stock drops 4.7% as investors await FDA decision on drug candidate relacorilant, with mixed trial results and analysts cautious outlook.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
